Female pelvic implants are surgically inserted in the vagina to treat disorders such as pelvic organ prolapse and stress urinary incontinence.
These disorders are responsible for affecting the life of women to a great extent and are prevalent mostly in the older generation. A treatment option available is surgical repair with or without prosthetic implants.
The market is strong in different regions worldwide, as this is one of the only available treatment options for pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The main products involved in the implantation process are vaginal mesh implants, vaginal grafts, vaginal slings and tapes.
The global female pelvic implants market registered a market value of more than $230m in 2017, which is expected to reach a value of more than $300m by the end of 2027. The market is anticipated to witness a sluggish compound annual growth rate (CAGR) of 2.8% during the forecast period.
Market dynamics of the female pelvic implants market
The female pelvic implants market is projected to witness a downfall and grow at a sluggish rate, marking a few issues that are limiting the growth of market.
The major issue pertains to complications associated with female pelvic implants. Surgeries that have taken place in the past have resulted in many health-related issues such as mesh erosion and infection. However there has been a shift in various countries towards the value-based healthcare model, which may help address this issue.
The governments and regulatory bodies of various countries are adopting cost-containment measures to reduce the healthcare burden, especially in developed economies. This shift from volume to value-based healthcare is driven by various measures taken by governments, providers, payers and life sciences companies, which include outcome-based pricing, profit and risk-sharing, price-control and competitive tendering. This may have a positive impact on the market in the coming years.
Female pelvic implants segmental outlook
China is expected to be an attractive region in the global market for female pelvic implants.
According to the report, China will register a CAGR of 4.7% during the forecast period. However, North America is anticipated to reach more than $80m by the end of 2027, making it the largest segment in terms of market value.
The growth of various regional female pelvic implants markets is mainly driven by rising geriatric populations and rises in the need for optimal methods to treat POP.
In terms of indication type, SUI has a higher market share than POP. SUI is expected to hold a market value of more than $190m by the end of 2027, growing at a CAGR of 3.6% during the forecast period. There is a significant rise in the rate of women suffering from SUI worldwide.
With the rapidly changing dynamics of the female pelvic implants market, many companies are hesitating in taking risks.
Manufacturers in the global market have faced more than 650 lawsuits alleging painful device-related injuries. Such complications have resulted in many major companies exiting the market.
However, there is hope for market players in developing regions where implant procedures are still prevalent. The companies that have exited the global market include Betatech, AMS, Promedon and Aspide Medical. On the other hand, companies that continue to prevail in the global market include Coloplast, Boston Scientific, PFM Medical and Ethicon.
To request a sample report, click here.
To find out more information about report methodology, click here.